Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 737

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease

Open access
Zheng, Lemin, Nukuna, Benedicta, Brennan, Marie-Luise, Sun, Mingjiang, Goormastic, Marlene, Settle, Megan, Schmitt, Dave, Fu, Xiaoming, Thomson, Leonor, Fox, Paul L., Ischiropoulos, Harry, Smith, Jonathan D., Kinter, Michael, Hazen, Stanley L. · 2004 · Journal of Clinical Investigation

Abstract

In recent studies we demonstrated that systemic levels of protein-bound nitrotyrosine (NO 2 Tyr) and myeloperoxidase (MPO), a protein that catalyzes generation of nitrating oxidants, serve as independent predictors of atherosclerotic risk, burden, and incident cardiac events.We now show both that apolipoprotein A-I (apoA-I), the primary protein constituent of HDL, is a selective target for MPO-catalyzed nitration and chlorination in vivo and that MPO-catalyzed oxidation of HDL and apoA-I results in selective inhibition in ABCA1-dependent cholesterol efflux from macrophages.Dramatic selective enrichment in NO 2 Tyr and chlorotyrosine (ClTyr) content within apoA-I recovered from serum and human atherosclerotic lesions is noted, and analysis of serum from sequential subjects demonstrates that the NO 2 Tyr and ClTyr contents of apoA-I are markedly higher in individuals with cardiovascular disease (CVD).Analysis of circulating HDL further reveals that higher NO 2 Tyr and ClTyr contents of the lipoprotein are each significantly associated with diminished ABCA1-dependent cholesterol efflux capacity of the lipoprotein.MPO as a likely mechanism for oxidative modification of apoA-I in vivo is apparently facilitated by MPO binding to apoA-I, as revealed by cross-immunoprecipitation studies in plasma, recovery of MPO within HDL-like particles isolated from human atheroma, and identification of a probable contact site between the apoA-I moiety of HDL and MPO.To our knowledge, the present results provide the first direct evidence for apoA-I as a selective target for MPO-catalyzed oxidative modification in human atheroma.They also suggest a potential mechanism for MPO-dependent generation of a proatherogenic dysfunctional form of HDL in vivo.that promote oxidative damage, cell injury, and conversion of LDL, the major carrier of cholesterol in plasma, into an atherogenic form (9, 14).Protein-bound nitrotyrosine (NO 2 Tyr), a posttranslational modification specific for protein oxidation by NO-derived oxidants (15-20), is markedly enriched within human atheroma (8, 21).Further, recent clinical studies demonstrate that systemic levels of protein-bound NO 2 Tyr serve as an independent predictor of atherosclerotic risk and burden in subjects and are modulated by known CVD risk-reducing therapies such as statins (10,22).Few studies to date have focused on defining the molecular targets of nitration in subjects with CVD, the attendant functional alterations, and the enzymatic participants in nitration.One potential enzymatic source for generation of NO-derived oxidants within human atheroma is the heme protein myeloperoxidase (MPO).MPO utilizes hydrogen peroxide (H 2 O 2 ) and a variety of low-molecular weight organic and inorganic substances as substrates to form reactive oxidant species capable of promoting protein halogenation, nitration, and oxidative cross-linking (4, 5).For example, MPO directly utilizes both NO (23) and the NO metabolite nitrite (NO 2 -) as substrates in vitro (17-19, 24) and participatesThe Journal of Clinical Investigation http://www.jci.org

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci200421109

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 5

  1. Baldus, 2001, J. Clin. Invest., 108, 1759, 10.1172/JCI200112617 · DOI
  2. Gaut, 2002, J. Clin. Invest., 109, 1311, 10.1172/JCI0215021 · doi:10.1172/jci0215021 · Paper page
  3. Hazen, 2000, Biochem. J., 3, 693, 10.1042/0264-6021:3520693 · doi:10.1042/0264-6021:3520693
  4. Woods, 2001, J. Cell. Biochem. Suppl., 37, 89, 10.1002/jcb.10069 · doi:10.1002/jcb.10069
  5. Singaraja, 2002, J. Clin. Invest., 110, 35, 10.1172/JCI0215748 · doi:10.1172/jci0215748 · Paper page

Cited by

See all 737

Metadata

Authors
Zheng, L., Nukuna, B., Brennan, M.-L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., Fox, P. L., Ischiropoulos, H., Smith, J. D., Kinter, M., & Hazen, S. L.
Venue
Journal of Clinical Investigation
Published
2004-08-16
Volume
114
Issue
4
Pages
529-541
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2107117207
Cited by
737
References
100
FWCI
15.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.